My speciality is in clinical cardiovascular diagnostics and I actively run academic research in the field of cardiovascular phenotyping of patients with ischemic heart disease and heart failure, as well as the development and validation of preclinical translational disease models. I am also Chief Physician at the Department of Cardiology at Sahlgrenska University Hospital and since 2009, I’ve held a professorship in translational cardiovascular research and drug discovery at Sahlgrenska Academy, Sahlgrenska University Hospital in Gothenburg, Sweden.

Since joining AstraZeneca more than 20 years ago, I’ve been involved in preclinical and clinical development of novel therapeutics using traditional small molecule approaches. I’m also involved in exploring non-small molecule modalities, including peptide, antibody, ASO, cell therapy, as well as mRNA, where I led the world´s first trial in humans using an mRNA platform.

Between 2007-2011, I was responsible for the atherosclerosis and heart failure pipeline and between 2011-2013,I worked as a Translational Science Director to help bridge the early projects into the human setting. 

In 2013, I was appointed Senior Director Physician in early clinical research unit and I’m responsible for Phase I and II clinical programs within the cardiovascular area. Since 2019, as Vice President and Head of Early Clinical Development in Early CVRM, I am accountable for global early clinical studies in cardiovascular, heart failure, diabetes, NASH and renal diseases. To date, together with my teams, we have brought a number of novel projects from target ideas through to preclinical translational research and into clinical proof of concept testing in the CVRM area.

My work in Early Clinical Development allows me to combine both traditional and cutting-edge translational research approaches to turn science into medicine. This is particularly relevant in CVRM where recent scientific advances are identifying novel targets and the important interplay between cardiovascular, heart failure, diabetes, NASH and renal diseases.

Li-Ming Gan Head of Early Clinical Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D


Searching for a cure for heart failure


Investigating cardiac regeneration to develop innovative therapies against heart failure using novel treatment modalities e.g. modified RNA


Building a unique imaging translational platform for proof of concept work from animals to humans


An innovative study using unique imaging capability to prove the adenosine mode of action of ticagrelor in man

  Featured publications

Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial.

Anttila V, Saraste A, Knuuti J, Jaakkola P, Hedman M, Svedlund S, Lagerström-Fermér M, Kjaer M, Jeppsson A, Gan LM.Mol Ther Methods Clin Dev. 2020;18:464-472. doi: 10.1016/j.omtm.2020.05.030.

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes.

Gan LM, Lagerström-Fermér M, Carlsson LG, Arfvidsson C, Egnell AC, Rudvik A, Kjaer M, Collén A, Thompson JD, Joyal J, Chialda L, Koernicke T, Fuhr R, Chien KR, Fritsche-Danielson R.Nat Commun. 2019;10(1):871. doi: 10.1038/s41467-019-08852-4.PMID: 30787295.

Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction

PROMIS-HFpEF. Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, Beussink-Nelson L, Fermer ML, Broberg MA, Gan LM, Lund LH. Eur Heart J. 2018;39(37):3439-3450. doi: 10.1093/eurheartj/ehy531.

Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases

Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Li-Ming Gan, Christer Betsholtz. Science  19 Aug 2016: Vol. 353, Issue 6301, pp. 827-830.

Non-invasive imaging of atherosclerosis in mice

Non-invasive real-time imaging of atherosclerosis in mice using ultrasound biomicroscopy. L Gan, J Grönros, U Hägg, J Wikström, C Theodoropoulos, P Friberg, Fritsche-Danielson R. Atherosclerosis 2007 190 (2), 313-320.

Translational coronary flow imaging in mice

Functional and morphologic imaging of coronary atherosclerosis in living mice using high-resolution color Doppler echocardiography and ultrasound biomicroscopy. J Wikström, J Grönros, G Bergström, L Gan. Journal of the American College of Cardiology 2005 46 (4), 720-727.

Proving the adenosine mode of action of ticagrelor.

Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, Gan LM. J Am Coll Cardiol. 2013: 61(7):723-7. doi: 10.1016/j.jacc.2012.11.032.

Veeva ID: Z4-35563
Date of preparation: July 2021